|
|
 |
|
Viewing report
|
|
|
|
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Decision Resources, Inc., May 2008, Pages: 32
Introduction
Demographic and cost data provide clear reasons for pharmaceutical industry investment in CVD biomarkers and diagnostics. CVDs are highly prevalent and potentially lethal diseases with high treatment costs; biomarkers offer the potential to decrease these costs by helping physicians to more efficiently manage CVD patients.
Get the Answers You Need to Shape Your Strategy
Debate surrounds the comparative value of new cardiac biomarkers versus established markers for risk assessment and prognosis. Have clinical studies supported the value of new cardiac biomarkers? Which new biomarkers have been shown to add independent capabilities for risk assessment and prognosis?
- The 2007 National Academy of Clinical Biochemistry (NACB) guidelines provide the most up-to-date thinking in biochemical diagnostic procedures for CVDs. Do these new guidelines support the use and value of cardiac biomarkers? Have these new guidelines seen aggressive uptake in the medical community?
- Point-of-care cardiac tests offer their own unique benefits to CVD care, but many debate their correlation with central laboratory tests. What are the economic benefits of these POC tests? Are POC tests proving to be better than central lab tests?
Scope
- Focus on use of biomarkers in three key CVDs: coronary heart disease (CHD), acute coronary syndrome (ACS), and chronic heart failure (CHF).
- Review of imaging technologies used for CVD: magnetic resonance imaging, computed tomography, positron emission tomography, single photon electron computed tomography, and near infrared fluorescence.
- Targeting of disease progression and risk stratification: genetic testing in CHD, biomarkers of plaque instability, serum markers for ACS and CHF.
- POC testing: economic benefits, comparison with central lab tests, top competitors.
- Strategic business models for CVD diagnostics: mergers and acquisitions, licensing activities.
- Investment considerations in CVD diagnostics: clinical validation and acceptance of new cardiac markers, need to control healthcare costs, debate over added value of new markers, increased investment in research, POC opportunities, improved modalities.
Customers who bought this item also bought
Cardiac Biomarkers - Global Strategic Business Report
Cardiac Biomarkers - A Global Market Perspective
Biomarkers - Technologies, Markets and Companies
Biomarkers 2008
Cardiac Markers Clinical Trial Analysis
Cardiovascular Biomarkers: Players, Products and Prospects (Volume III)
Cardiac Marker Diagnostic Testing Markets
Risk Stratification in the Diagnosis of Cardiovascular Disease
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Advances in Biomarkers
Cardiac Markers Pipeline Technology and Market Forecasts to 2015
|
|
|
|
